Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

Inhibitors of poly(ADP‐ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In our study, of 182 women with EOC treated with PARPi, 16 (8.7%...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Todisco, Elisabetta, Gigli, Federica, Ronchini, Chiara, Amato, Viviana, Sammassimo, Simona, Pastano, Rocco, Parma, Gabriella, Lapresa, Maria Teresa, Bertolini, Francesco, Corsini, Chiara, Gregato, Giuliana, Poletti, Claudia, Pelicci, Pier Giuseppe, Alcalay, Myriam, Colombo, Nicoletta, Tarella, Corrado
Aineistotyyppi: Online Artikkeli Teksti
Kieli:English
Julkaistu: John Wiley & Sons, Inc. 2022
Aiheet:
Cancer Therapy and Prevention
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Samankaltaisia teoksia